Matt Hall Profile picture
🇦🇺 Director, Early Translation Branch @ncats_nih_gov @nih rare diseases, #COVID19 & the next pandemic. Views my own.
Dec 11, 2020 24 tweets 8 min read
So here's an update on the abandoned UQ COVID vaccine named UQ-CSL v451

uq.edu.au/news/node/1279… First, the release states that the vaccine worked: vaccine elicited a response and "There were no serious adverse events or safety concerns reported in the 216 trial participants"
Dec 10, 2020 4 tweets 2 min read
WELL I'm going to have to dig into this. Reminder that vaccine development is not straightforward, despite the super-exciting day we are having watching #VRBPAC

Australian COVID vaccine terminated due to HIV ‘false positives’ smh.com.au/politics/feder… "The UQ vaccine candidate uses a protein and adjuvant platform, containing the COVID-19 spike protein and a "molecular clamp". A small component is derived from.... HIV, that is not able to infect people or replicate."

Any details out there?
Dec 9, 2020 7 tweets 3 min read
Our @NIHDirector says @ncats_nih_gov have been "everywhere you look" on COVID-19 science !!

Part of a @MilkenInstitute Conversation with Dr. Francis Collins, Director, @nih (and Michael Milken)

vimeo.com/486353483 There were three examples that @NIHDirector gave.

First, tackling a battery of assays, screening of all libraries for SARS-COV-2, and sharing data openly through our OpenData Portal

opendata.ncats.nih.gov/covid19
Sep 13, 2020 4 tweets 2 min read
Well - huge issues here. Not sure this article will be around for long.

And it's just samples collected for a completely different study (on asthma), and they checked TMPRSS2.

"Race" isn't mentioned in the awarded R01 - it's an asthma grant from NIAID.
grantome.com/grant/NIH/R01-… I have a terrible feeling that ran TMPRSS2 expression on their samples, looked for a differential based on what they know about study sample donors (rather than having a hypothesis), and were like "welp, 'race' is a thing with COVID let's go with that".
Apr 5, 2020 14 tweets 6 min read
OK so let's talk about camostat, because I'm starting to worry about it as a #COVID19 repurposing candidate. It emerged based on this Cell paper, but a LOT of assumptions are buried in the science.
cell.com/cell/fulltext/… Image That Cell paper calls camostat "calls camostat “a clinically proven inhibitor of the cellular serine protease TMPRSS2” – which is not strictly correct.

It’s a clinically used drug (in Japan)

It has been shown to act on TMPRSS2 indirectly

Separate points. @Dereklowe
Jan 30, 2019 11 tweets 3 min read
This article on a 'miracle cure' for cancer has me so angry. How can unpublished, non-peer reviewed tripe get any attention at all? Some of the issues are in the thread below:
jpost.com/HEALTH-SCIENCE… First, the experimental theraputic modality is based on phage-display-derived peptides against various targets that are apparently coupled together with a 'peptide toxin'. Presumably the peptide toxin is Monomethyl auristatin E